Peter Múdry (Peter Mudry)

ORCID

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Venues

Scientific reports

Cancers

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Sterba, Petra Pokorna, Renata Faberova, Blanka Pinkova, Jarmila Skotakova, Anna Seehofnerova, Jan Blatny, Lucia Janigova, Olga Koskova, Hana Palova, Michal Mahdal, Lukas Pazourek, Petr Jabandziev, Ondrej Slaby, Peter Múdry, Jaroslav Sterba
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Scientific reports 13 (1) (2023)
Martin Sterba, Petra Pokorna, Renata Faberova, Blanka Pinkova, Jarmila Skotakova, Anna Seehofnerova, Jan Blatny, Lucia Janigova, Olga Koskova, Hana Palova, Michal Mahdal, Lukas Pazourek, Petr Jabandziev, Ondrej Slaby, Peter Múdry, Jaroslav Sterba
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Scientific reports 13 (1) (2023)
Michal Mahdal, Tomáš Tomáš, Vasileios Apostolopoulos, Dagmar Adámková, Peter Múdry, Iva Zambo, Lukáš Pazourek
Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone. Cancers 15 (18) (2023)
Martin Sterba, Petra Pokorna, Renata Faberova, Blanka Pinkova, Jarmila Skotakova, Anna Seehofnerova, Jan Blatny, Lucia Janigova, Olga Koskova, Hana Palova, Michal Mahdal, Lukas Pazourek, Petr Jabandziev, Ondrej Slaby, Peter Múdry, Jaroslav Sterba
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Scientific reports 13 (1) (2023)
Martin Sterba, Petra Pokorna, Renata Faberova, Blanka Pinkova, Jarmila Skotakova, Anna Seehofnerova, Jan Blatny, Lucia Janigova, Olga Koskova, Hana Palova, Michal Mahdal, Lukas Pazourek, Petr Jabandziev, Ondrej Slaby, Peter Múdry, Jaroslav Sterba
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Scientific reports 13 (1) (2023)

Peter Múdry.css-eqlu8i{font-size:small;padding-left:4px;} (Peter Mudry)

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Múdry (Peter Mudry)